Literature DB >> 1611715

Increases in soluble CD8 antigen in plasma, and CD8+ and CD8+CD38+ cells in human immunodeficiency virus type-1 infection.

M J Yagi1, F N Chu, J D Jiang, J Wallace, P Mason, Y Liu, J Carafa, J G Bekesi.   

Abstract

Increases in plasma levels of soluble CD8 (SCD8) antigen and expansion of the CD8+ CD38+ lymphocyte compartment were early immunologic alterations frequently observed prior to detection of antibodies against human immunodeficiency virus type 1 (HIV-1) and diminution of CD4+ cells in subjects at risk to develop AIDS. These increases identified in the 49 seronegative homosexual men were manifest in all 164 homosexual subjects and 45 intravenous drug users (IVDU) positive for HIV-1 antibodies (HIV-1+), 19 patients with ARC, and 29 AIDS patients. Augmentation of plasma sCD8 antigen correlated with increases in both CD8+ and CD8+ CD38+ cells in HIV-1(-) homosexual men (r = 0.35, P less than 0.013; r = 0.48, P less than 0.0005; respectively) and the 258 HIV-1+ subjects (r = 0.25, P less than 0.0003; r = 0.33, P less than 0.0001, respectively). In vitro examination of unstimulated peripheral blood lymphocytes from HIV-1+ homosexuals and IVDU confirmed the fivefold higher constitutive levels of cellular release of sCD8 antigen in these subjects compared to heterosexual controls. Inclusion of radiolabeled amino acids during the 3-day culture period in the presence or absence of phytohemagglutinin resulted in negligible levels of radioactivity associated with the sCD8 antigen indicative of a lack of de novo synthesis. Throughout clinical progression to AIDS, sCD8 antigen levels continued to escalate relative to the numbers of CD8+ cells bearing CD38+ antigen. The data confirm the interrelationship between sCD8+ antigen and CD8+ and CD8+ CD38+ cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1611715     DOI: 10.1016/0090-1229(92)90004-8

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  8 in total

1.  Prognostic significance of cytotoxic T cells in individuals infected with human immunodeficiency virus.

Authors:  C Mihailov; A Lamour; V Beaudré-Bellein; N Jézequel; M Garré; D Mottier; G Guillet; P Youinou
Journal:  J Clin Immunol       Date:  1993-03       Impact factor: 8.317

Review 2.  Positive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesis.

Authors:  K Ikuta; S Suzuki; H Horikoshi; T Mukai; R B Luftig
Journal:  Microbiol Mol Biol Rev       Date:  2000-12       Impact factor: 11.056

3.  Concentrations of soluble CD95 and CD8 antigens in the plasma and levels of CD8+CD95+, CD8+CD38+, and CD4+CD95+ T cells are markers for HIV-1 infection and clinical status.

Authors:  J D Jiang; M Schlesinger; H Sacks; D Mildvan; J P Roboz; J G Bekesi
Journal:  J Clin Immunol       Date:  1997-03       Impact factor: 8.317

Review 4.  Markers predicting progression of human immunodeficiency virus-related disease.

Authors:  C M Tsoukas; N F Bernard
Journal:  Clin Microbiol Rev       Date:  1994-01       Impact factor: 26.132

5.  Activation of tumor necrosis factor--alpha system in HIV-1 infection: association with markers of immune activation.

Authors:  P Aukrust; N B Liabakk; F Müller; T Espevik; S S Frøland
Journal:  Infection       Date:  1995 Jan-Feb       Impact factor: 3.553

6.  Biomarkers predicting progression of human immunodeficiency virus-related disease.

Authors:  Amar Kanekar
Journal:  J Clin Med Res       Date:  2010-03-11

7.  Markers of immune activation: novel biomarkers to predict the early-warning indicator of patients with papillary thyroid carcinoma.

Authors:  Hongsheng Lu; Lihong Zhang; Yuechu Dai; Yanyun Ruan; Xuequan Cao; Xiaobo Cai; Sihan Ruan; Qi Chen
Journal:  Diagn Pathol       Date:  2020-02-12       Impact factor: 2.644

Review 8.  Roles of CD38 in the Immune Response to Infection.

Authors:  Estibaliz Glaría; Annabel F Valledor
Journal:  Cells       Date:  2020-01-16       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.